ASCRS 2024: 10-year results from a real-world study shed new light on glaucoma

News
Video

At ASCRS in Boston, Paul Harasymowycz, MD shared a decade's worth of data on MIGS procedures for primary open-angle glaucoma

At this year's ASCRS meeting in Boston, Massachusetts, we caught up with Paul Harasymowycz, MD, who detailed his presentation "Decade-Long Outcomes of Two First-Generation Trabecular Micro-Bypass Stents with Cataract Surgery in Primary Open-Angle Glaucoma." Here, he shares the highlights from a decade's worth of data.

Editor's note: The below transcript has been lightly edited for clarity.

Hello, I'm Dr Paul Harasymowycz, from University of Montreal and McGill University. Today we have the pleasure of presenting our 10-year results of using two [first-generation trabecular micro bypass] iStents with cataract surgery. So that's a decade of results using MIGS surgery. I think that's a very important contribution to our knowledge.

This was a real world study. In the end, we had 56 patients that we followed over time. The most important is that they had OCT stability up until 10 years. The average pressure before was higher than 18. And even after 10 years, a decade, their pressure was almost at 14. That's very important. Another finding in our study was that 75% of our patients, their pressure was below 15. And we know, usually, the lower we keep the pressure, the less likelihood is that their glaucoma will progress. And so I think that's great for our patients. In the end, it's all about the patients. And the study does show that using angle surgery may be beneficial to your patients as well.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.